Strategies to investigate circulating endothelial cells in cancer

Research output: Contribution to journalArticlepeer-review


There is an increasing evidence of the crucial role of angiogenesis in cancer, and randomized studies have indicated that a "pure" anti-angiogenic drug (the anti-VEGF antibody Avastin) is very effective in colorectal cancer. In addition, this and other anti-angiogenic drugs have demonstrated activity and are currently under clinical investigation in a variety of other cancer types. At the present time, however, there is a scarcity of useful endpoints for treatment outcome beside survival. Using flow cytometry, quantitative PCR and cell culture we have found that circulating endothelial cells and progenitors are increased in cancer patients, and that measuring their viability and kinetics may offer significant clinical insight in the management of cancer patients.

Original languageEnglish
Pages (from-to)503-506
Number of pages4
JournalPathophysiology of Haemostasis and Thrombosis
Issue number5-6
Publication statusPublished - 2003


  • Cancer
  • Circulating endothelial cells

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Strategies to investigate circulating endothelial cells in cancer'. Together they form a unique fingerprint.

Cite this